Pharmaceutical case studies illustrating data analytics strategies
New webinar hosted by Xtalks focuses on extracting the most value from data assets.
In this live broadcast, Lisa J. Graham, CEO and Founder of Alkemy Innovation, and Brian Crandall, Analytics Engineer at Seeq, will discuss new data analytics strategies that can enable and redefine biopharmaceutical businesses. The webinar takes place on Monday 12, June 2017 at 11 am EDT (4 pm BST/UK).
Data Rich, Information Poor. Choosing the appropriate data management and visualization components are important. How many times have you wanted to investigate a key issue, or proactively design a new process, only to be stopped in your tracks because you don't have the data you need? Do you often decide that the pain and effort of gathering the data, that you know exists somewhere, isn't worth the time it takes to pull it together?
With the invent of high-speed, high-throughput data acquisition capabilities of recent years, there is a need for high-speed data analytics and visualization. Analytics tools are the most efficient way to get the most value out of the data that is being produced every day. With the proper tools in hand, your data can become one of your greatest assets.
Yet, most processing is still done in user-specific spreadsheets with time-consuming, manual inputs and calculations. Further, when challenges arise, it becomes necessary to couple reams of disparate data sources, often in multiple iterations, to better understand the complex reactor, bioreactor, or purification dynamics.
It is not uncommon for a technical team to need to leverage significant historical data within very tight product development timelines. Therapies need to be quickly transitioned from a proof-of-concept phase to a scale and quality suitable for commercial production, where the company must also demonstrate full knowledge of both the process and the final product quality metrics. With that knowledge, the company can achieve a successful launch, ensure patient safety, and meet regulatory requirements. Data is a tremendous asset that should be captured and made readily available for analysis, which is imperative for
In this webinar, the speakers will focus on specific pharmaceutical case study examples, with a focus on the Seeq software application. Seeq simplifies the extraction of insights and value from data historians and other data sources. Specifically, it allows the scientist or engineer to quickly access and search the data, add context, cleanse, model, find patterns, establish boundaries, monitor assets, and allow collaboration in real time. Our expert speakers will discuss how you can leverage data analytics strategies to achieve
Scientists in pharmaceutical production must be able to thrive in a challenging business environment defined by operational challenges, regulations, market shifts, and competition.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance